Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
July 06, 2021 07:30 ET
|
Kura Oncology, Inc.
– Combination of tipifarnib and alpelisib shows robust activity in preclinical PDX models of HRAS and PIK3CA pathway dependent tumors – – HNSCC accounts for more than 500,000 new cancer cases each...
Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539
June 24, 2021 08:30 ET
|
Kura Oncology, Inc.
– Phase 1b expansion cohorts designed to enable refinement of recommended Phase 2 dose – – At least 12 patients to be enrolled in each of two Phase 1b expansion cohorts: a 200 mg dose cohort and a...
Kura Oncology to Participate in JMP Securities Life Sciences Conference
June 10, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Appoints Carol Schafer to Board of Directors
June 04, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit
May 13, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Reports First Quarter 2021 Financial Results
May 06, 2021 16:04 ET
|
Kura Oncology, Inc.
– Menin inhibitor KO-539 continues to demonstrate compelling clinical activity, favorable safety/tolerability and a wide therapeutic window – – KOMET-001 trial amended to include Phase 1b expansion...
Kura Oncology to Report First Quarter 2021 Financial Results
April 29, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology
March 22, 2021 16:08 ET
|
Kura Oncology, Inc.
– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC – – Statistically significant improvement in median PFS...
Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results
February 24, 2021 07:20 ET
|
Kura Oncology, Inc.
– Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations – – KO-539 continues to demonstrate a...
Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma
February 24, 2021 07:00 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...